Safety and heart rate changes in Covid-19 patients treated with Remdesivir.
Cardiovascular Toxicity
Covid-19
Heart Rate
Remdesivir
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
03
07
2021
revised:
11
09
2021
accepted:
15
09
2021
pubmed:
23
9
2021
medline:
15
12
2021
entrez:
22
9
2021
Statut:
ppublish
Résumé
Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir. We present a case series of 52 patients who underwent daily electrocardiogram (ECG) examination after Remdesivir administration. Compared to baseline, a significant heart rate reduction was observed after initiation of Remdesivir; however, no case of severe bradycardia or arrhythmias leading to significant clinical complications or Remdesivir discontinuation occurred. Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001). By multivariate analysis, a less severe clinical presentation of Covid-19 (beta=0.47, p<0.01) was related to lower heart rate levels observed after Remdesivir administration. Despite a significant reduction in heart rate observed after Remdesivir administration, no severe cardiovascular toxicity was observed in Covid-19 patients, even in the case of cardiovascular comorbidities.
Identifiants
pubmed: 34551344
pii: S1201-9712(21)00741-4
doi: 10.1016/j.ijid.2021.09.036
pmc: PMC8451471
pii:
doi:
Substances chimiques
Antiviral Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
254-257Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.